Sponsored by DaVita and other industry leaders, this four-year effort offers clinicians evidence-based tools to help operationalize new standards: Goal: Establish best practices for interdisciplinary care impacting 250,000+ patients
In the phase 2 trial, the most common adverse events were gastrointestinal: nausea (25% at the 12 mg dose), diarrhea (22%), vomiting (11%), and decreased appetite [1]
We believe that the best candidates for Ozempic are those who are highly motivated and committed to making significant lifestyle changes
Mild nausea, slight appetite loss, and occasional digestive changes occur in some patients but are generally manageable at the low starting dose
A patient who assumed Hepatitis C was behind them, never had a recent FibroScan, and started semaglutide develops a more sustained enzyme elevation along with right-upper-quadrant discomfort